VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Announces Publication of Preclinical Data for the Company’s Avian Flu Vaccine Candidate in PLoS ONE Journal

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals Inc. (VGX) announced today the publication in PLoS ONE - an international, peer-reviewed, open-access, online publication - of preclinical data for the Company’s preventative DNA vaccine candidate for avian influenza, VGX-3400. The article, titled “Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens”, is available at www.plosone.org/doi/pone.0002517.